Cholesterol, obesity treatment: New drug shows promise in mice

Evan Walker
Evan Walker TheMediTary.Com |
red table laid with two napkins and two sets of cutleryShare on Pinterest
A thyroid hormone-mimicking drug delivered straight to the liver may reduce cholesterol levels and reverse obesity. Image credit: Alan Powdrill/Getty Images.
  • More than 1 billion people worldwide have obesity.
  • About 28.5 million people globally have high cholesterol.
  • Both conditions increase a person’s risk for other diseases such as cardiovascular disease and diabetes.
  • Researchers from the University of Massachusetts Amherst have designed a nanogel-based carrier to deliver a drug that mimics synthetic thyroid hormone directly to the liver.
  • Scientists found via a mouse model that this liver-targeted drug system helped obese mice return to a Healthy weight and lower their cholesterol levels.

More than Health Organization" rationale="Highly respected international organization">1 billion people have obesity — a condition where a person has more weight or body fat than what most doctors consider Healthy for their height and age.

Furthermore, about 28.5 million people around the world have high cholesterol, where a person has too much cholesterol in their body, which builds up inside their arteries and makes it hard for blood to flow properly.

People who are obese and/or have high cholesterol are at a higher risk for other diseases such as cardiovascular disease, high blood pressure, diabetes, and even certain types of cancer.

Now, researchers from the University of Massachusetts Amherst have designed a nanogel-based carrier to deliver a drug that mimics synthetic thyroid hormone directly to the liver.

Scientists found via a mouse model this liver-targeted drug system helped obese mice return to a healthy weight and lower their cholesterol levels.

This study was recently published in the journal PNAS NEXUS.

For this study, researchers engineered a nanogel-based carrier to deliver a drug directly to the liver.

Dr. S. Thai Thayumanavan, distinguished professor of chemistry and biomedical engineering, department head of biomedical engineering, director of the Center for Bioactive Delivery at the University of Massachusetts Amherst, and lead author of this study explained to Medical News Today:

“Our nanogels have an inherent propensity to home in the liver and then there is a specific need for targeting the hepatocytes in the liver when it comes to metabolic disorders. Therefore, we decorated these nanogels with additional chemical functionalities such that they will not only prefer to home in on the liver but also will be taken up by hepatocytes of the liver.”

The drug Dr. Thayumanavan and his team used in this study is a thyromimetic — a drug that mimics synthetic thyroid hormone.

“The drug is thought to target the thyroid hormone receptor beta, which is found throughout the body but predominantly in the liver,” he said.

“Our drug’s interaction with this receptor is responsible for activating a number of physiological responses, including fatty acid oxidation and reverse cholesterol pathway (RCT), which may be the cause of the observed weight loss and lowering of cholesterol,“ explained Dr. Thayumanavan. “However, much more work needs to be done to confirm this hypothesis.”

Dr. Thayumanavan further noted that thyroid hormone mimics have been previously tested as cholesterol-lowering agents and are currently in clinical trials for the treatment of nonalcoholic steatohepatitis (NASH).

However, he said there have historically been two major issues — the bioavailability of these drugs and possible off-target effects when these thyromimetics reach other organs.

“Thyroid hormone mimics that are being tested in the clinic for NASH — and which are doing quite well — are of low potency so you’re not getting the full potential of the drug,” Dr. Thayumanavan continued. “Our thinking was that by combining a potent thyromimetic with our nanogel, we could eliminate toxicity associated with systemic exposure and gain activity by concentrating the drug at the site we wanted.”

There are a number of diseases that can negatively affect the liver, causing potential repercussions for the rest of the body. One of these is fatty liver disease, which occurs in conjunction with obesity.

A study published in September 2022 found that high cholesterol can not only make fatty liver disease worse but can lead to longer-term liver scarring and immune cell dysfunction.

High cholesterol can also cause inflammation of the liver, increasing the risk for other liver diseases and damage.

Conversely, an inflamed liver may reduce the production of bile, resulting in high cholesterol levels in the body.

TAGGED: , ,
Share this Article